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Abstract
AIM
To investigate of pediatric ulcerative colitis activity 
index (PUCAI) in ulcerative colitis correlate with 
mucosal inflammation and endoscopic assessment of 
disease activity (Mayo endoscopic score).
METHODS
We reviewed charts from ulcerative colitis patients 
who had undergone both colonoscopy over 3 years. 
Clinical assessment of disease severity within 35 
d (either before or after) the colonoscopy were 
included. Patients were excluded if they had significant 
therapeutic interventions (such as the start of cor-
ticosteroids or immunosuppressive agents) between 
the colonoscopy and the clinical assessment. Mayo 
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ORIGINAL ARTICLE
Correlation of endoscopic disease severity with pediatric 
ulcerative colitis activity index score in children and young 
adults with ulcerative colitis
Observational Study
Basavaraj Kerur, Heather J Litman, Julia Bender Stern, Sarah Weber, Jenifer R Lightdale, Paul A Rufo, 
Athos Bousvaros
endoscopic score of the rectum and sigmoid were done 
by two gastroenterologists. Inter-observer variability in 
Mayo score was assessed.
RESULTS
We identified 99 patients (53% female, 74% pancolitis) 
that met inclusion criteria. The indications for colonoscopy 
included ongoing disease activity (62%), consideration 
of medication change (10%), assessment of medication 
efficacy (14%), and cancer screening (14%). Based on 
PUCAI scores, 33% of patients were in remission, 39% 
had mild disease, 23% had moderate disease, and 4% 
had severe disease. There was “moderate-substantial” 
agreement between the two reviewers in assessing rectal 
Mayo scores (kappa = 0.54, 95%CI: 0.41-0.68). 
CONCLUSION
Endoscopic disease severity (Mayo score) assessed by 
reviewing photographs of pediatric colonoscopy has 
moderate inter-rater reliability, and agreement was less 
robust in assessing patients with mild disease activity. 
Endoscopic disease severity generally correlates with 
clinical disease severity as measured by PUCAI score. 
However, children with inflamed colons can have 
significant variation in their reported clinical symptoms. 
Thus, assessment of both clinical symptoms and endos-
copic disease severity may be required in future clinical 
studies.
Key words: Ulcerative colitis; Pediatric ulcerative colitis 
activity index; Mayo score
© The Author(s) 2017. Published by Baishideng Publishing 
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Core tip: There is controversy regarding what the 
best method of assessing disease activity in pediatric 
ulcerative colitis. Currently, the best accepted tool is 
the pediatric ulcerative colitis activity index (PUCAI), 
developed by Turner and colleagues, which is a 
physician reported measure. Because of its formal 
validation and ease of use, the PUCAI has been widely 
accepted both as a clinical tool by physicians. Other 
experts have suggested that biomarkers, patient 
reported outcomes, or endoscopic disease activity may 
be better measures. In this study, we show physicians 
looking at endoscopic photos may grade the Mayo 
endoscopic scores differently, and that the PUCAI 
generally correlates well with endoscopic disease 
activity. 
Kerur B, Litman HJ, Stern JB, Weber S, Lightdale JR, Rufo PA, 
Bousvaros A. Correlation of endoscopic disease severity with 
pediatric ulcerative colitis activity index score in children and 
young adults with ulcerative colitis. World J Gastroenterol 2017; 
23(18): 3322-3329  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i18/3322.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i18.3322
INTRODUCTION
The development of proper measures to assess 
the response to drug therapy in pediatric inflamma­
tory bowel disease is an important priority for both 
clinicians and regulatory agencies. Currently, there 
are many different disease activity indices utilized in 
published studies of adult inflammatory bowel disease 
(IBD)[1,2]. In children, Turner and colleagues developed 
the pediatric ulcerative colitis activity index (PUCAI) in 
2007, based on input from a Delphi group of thought 
leaders, and development of individual criteria utilizing 
state of the art statistical methodology[3]. The PUCAI 
score is based on 6 quantifiable items (abdominal pain, 
stool frequency, stool consistency, amount of blood 
in the stool, nocturnal diarrhea, and well­being). The 
PUCAI has been widely used by clinicians in studies of 
drug efficacy, and has also been utilized in assessing 
the efficacy of surrogate markers[4,5]. In a recent trial 
of infliximab, PUCAI scores were useful in predicting 
the important outcome of sustained steroid­free clinical 
remission at 1 year[6]. Physician reported PUCAI scores 
also correlate well with patient self­reported PUCAI 
scores[7].
Recently, physicians at regulatory agencies have 
suggested that the PUCAI may not be an optimal 
measure of disease activity in clinical trials[8]. The 
PUCAI is a clinician reported outcome rather than 
patient reported outcome. In addition, the PUCAI does 
not contain information about mucosal inflammation 
or endoscopic remission (mucosal healing). There is 
an increasing amount of literature on the importance 
of mucosal healing (aka reduction in endoscopic 
inflammation) as an aim of treatment in ulcerative 
colitis[9]. Mucosal healing may change the natural 
history of UC and improve clinical outcomes[10,11]. 
Direct examination of the colonic mucosa has be­
come the preferred method of measuring disease 
activity in adult UC trials[12,13]. The physician’s clinical 
assessment of active disease in ulcerative colitis (UC) 
may not correlate well with mucosal inflammation and 
endoscopic assessment of disease activity[14]. Often 
endoscopic and histologic disease activity in UC lags 
behind improvement in clinical symptoms[15].
The Mayo endoscopic score is a commonly utilized 
measure of disease severity in adult clinical trials, 
and has been utilized in multiple studies, including 
the ACT 1 and 2 trials of infliximab, and the recent 
vedolizumab UC trial[16,17]. However, the inter­rater 
reliability of the Mayo endoscopic score has not been 
adequately assessed in pediatrics. In addition, limited 
data exists comparing clinical disease activity (PUCAI) 
to endoscopic disease activity (Mayo score)[18].
To address these questions, we conducted a 
retrospective study comparing clinical disease activity 
to endoscopic photos in our pediatric and young 
adult ulcerative colitis population that has undergone 
endoscopic assessment unrelated to clinical trial 
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participation. The primary aim of our study was to 
assess the correlation between endoscopic disease 
activity (Mayo score) and clinical disease activity 
(PUCAI) in UC. We also sought to assess if expert 
clinicians looking at endoscopic photos would give 
similar Mayo scoring of disease activity (Inter observer 
variability). Our primary outcome was agreement 
between ratings of disease activity as measured by 
both scores, while we used ratings by two independent 
physician reviewers to determine interrater agreement 
of Mayo scores.
MATERIALS AND METHODS
Chart review
This was a retrospective study performed at Boston 
Children’s Hospital. We utilized our IBD center database 
to identify ulcerative colitis patients who underwent 
colonoscopy over last 3 years. We have utilized the 
Probation endoscopy software for our colonoscopy 
reporting, and colonoscopy photographs are taken at 
the discretion of the endoscopist. For inclusion in this 
study, we allowed only one procedure per patient (i.e., 
patients with more than one procedure only had their 
first procedure selected). Reports were reviewed by 
research coordinators (SW, JBS) for the presence of at 
least one photograph of the rectum and/or sigmoid. 
In addition, charts were reviewed for clinical disease 
severity (PUCAI score) by the study physician (BK). 
In a subset of charts, PUCAI had been entered by the 
treating physician at the time of clinic visit. In other 
cases, the PUCAI score was calculated based on data 
abstracted from the chart. Because of the retrospective 
nature of this study, endoscopic and clinical assess­
ments were not always performed on the same day. 
We included data to allow comparisons between 
endoscopic and clinical disease activity as long as there 
was no change in the clinical status of the patient, no 
addition of new medications, and no change in the 
dose of aminosalicylates, immunomodulators, and 
biologics between assessments.
Inter-rater reliability of mucosal inflammation
Two physicians with expertise in IBD endoscopy 
and grading of mucosal inflammation (AB and PR) 
independently reviewed photographs taken of the 
rectum and/or sigmoid. A standard photographic 
reference guide to Mayo scoring developed for an 
industry clinical trial was utilized by both physicians as 
a reference[19]. Physicians were blinded as to the clinical 
disease activity score and to the endoscopic score 
from the other physician. A Mayo score of “0” was 
assigned when mucosal findings were consistent with 
normal or inactive disease; “1” indicated mild disease, 
as characterized by erythema, decreased vascular 
pattern, mild friability; “2” was assigned when mucosal 
findings suggested moderate disease, as characterized 
by marked erythema, absent vascular pattern, friability 
and erosions; and a score of “3” was assigned when 
mucosal images showed severe disease, characterized 
by mucosal evidence of spontaneous bleeding and 
ulceration.
The rectum and sigmoid were scored independently 
by each rater. If one region was scored but the other 
was not, the region not scored was treated as missing 
data. 
Correlation between PUCAI and Mayo score
For this analysis, we utilized the PUCAI abstracted 
or calculated from the chart, as well as individual 
components of the PUCAI (e.g., amount of rectal 
bleeding), and correlated it to the rectal and sigmoid 
Mayo scores. Since in some patients, PUCAI was not 
obtained on the same day as the endoscopic score, 
we allowed up to 35 d between the endoscopic score 
and the clinical score, as long as there had been no 
significant change in medical therapy (see above). If 
there was disagreement between the two physicians 
(AB and PR) on Mayo score, a third physician (JL) gave 
an independent blinded assessment of Mayo score, 
and the score chosen by two of the three reviewers 
was utilized. 
Statistical analysis
To assess agreement of Mayo score between the two 
reviewers, Cohen’s kappa was calculated. If the kappa 
value was greater than 0.5, the two reviewers were 
considered to concur with reasonable agreement 
(0.01­0.20 slight, 0.21­0.40 fair, 0.41­0.60 moderate, 
0.61­0.80 substantial, 0.81­0.99 almost perfect)[20]. 
Observations categorized as unknown were excluded 
from the kappa calculation. The percent agreement 
between the two reviewers was also calculated. 
To assess the primary outcome of the correlation 
between PUCAI and Mayo scores, assuming a 5% two­
sided significance level and the 99 available subjects, 
we have 80% power to detect whether a correlation 
coefficient of 0.27 or higher (R­squared value of at 
least 0.07) differs from 0 (nQuery Advisor Version 
7.0, 1995­2007, Janet D. Elashoff). One­way ANOVA 
modeling was used to assess the relationship between 
continuous PUCAI and Mayo scores. Considering 
the Mayo scores as 0/1 and 2/3 with categorical 
PUCAI scores, a Cochran­Armitage test of trend 
was used to investigate whether a relationship held. 
Pearson’s correlation coefficients were used to assess 
correlations between subcomponents of the PUCAI and 
Mayo scores. Data was abstracted and entered into an 
SPSS database. Statistical analysis was performed by 
a biostatistician utilizing SAS Version 9.3 (SAS Institute 
Inc, Cary, NC). A 5% two-sided significance level was 
used for all statistical testing. 
Ethical review
This study was conducted under a protocol for chart 
review approved by the Children’s Hospital Committee 
3324 May 14, 2017|Volume 23|Issue 18|WJG|www.wjgnet.com
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rectum or the sigmoid colon. Of the 99 procedures, 
18 did not have adequate rectal photography, while 5 
did not have photos of the sigmoid. Not including the 
18 in the “unknown” category, the percent agreement 
between the two reviewers for the rectum measure 
was 68% and the Cohen’s kappa value (95%CI) 
was calculated to be 0.54 (0.41, 0.68), indicating 
“moderate­substantial” agreement between the two 
graders (Table 2) In contrast, there was less agreement 
(60%) in the sigmoid scoring. For the sigmoid, Cohen’s 
kappa value (95%CI) was calculated to be 0.44 (0.32, 
0.56), consistent with “fair­moderate agreement” 
(Table 3). Details of the data collection is in shown in 
Table 4.
Correlation between Mayo and PUCAI scores
For this analysis, we compared the endoscopic severity 
(Mayo score) at time of colonoscopy with clinical 
disease severity (PUCAI) from a proximal clinic visit or 
inpatient assessment. For the comparison, we utilized 
the common Mayo score if both endoscopy raters 
agreed, or the three rater consensus score if the two 
raters disagreed. In our population, PUCAI scores were 
obtained before colonoscopy in 30% of patients, and 
after colonoscopy in 70% of patients. The median time 
between endoscopic assessment and calculation of 
PUCAI score was 14 d, interquartile range 5­21 d, and 
91% of scores were obtained within 30 d. 
There was strong correlation between Mayo 
endoscopic score of disease severity in the rectum 
and PUCAI (Figure 1; R­squared = 0.43, P < 0.001). 
Similarly, there was strong correlation between 
sigmoid inflammation and PUCAI (R-squared = 0.25, 
P < 0.001, data not shown). However, within each 
stratum of PUCAI score, there was variability within 
on clinical investigation.
RESULTS
Demographics
We identified 163 colonoscopies performed in children 
and young adults with ulcerative colitis performed 
during the study period. Of these, we excluded 
64 procedures because they were either duplicate 
procedures on the same patient, there were no 
adequate colonoscopy photos to assess mucosal 
inflammation, there was no clinic visit in proximity 
to the endoscopy, or medical interventions had been 
performed between the colonoscopy and the clinical 
assessment that would affect disease activity. The 
final population for analysis was 99 patients, with 
demographics of the study population provided in 
Table 1. There were 47 males and 52 females, with 
a median age of 16 years. Most patients (82%) had 
had colitis for 1 year or more; 68% were receiving 
treatment with aminosalicylates, and 45% were 
receiving either thiopurines, methotrexate, or anti­TNF 
therapy. 
Inter-rater reliability of colonoscopy photos
For this analysis, the inter­rater reliability of two 
different regions (rectum and sigmoid) was compared. 
All patients had at least one interpretable photo of the 
Table 1  Descriptive information regarding the dataset (n = 99) 
Characteristic n  (%) 
Gender
   Male 47 (47)
   Female 52 (53)
Ulcerative colitis (UC) duration - scope
   New onset 1 (1)
   < 1 yr 16 (16)
   1-3 yr 30 (30)
   3-5 yr 16 (16)
   > 5 yr 36 (36)
Indication for procedure
   Suspicion of UC 1 (1)
   Active symptoms 61 (62)
   Consideration of Medication change 10 (10)
   Assessment of Medication efficacy 13 (14)
   Cancer screening 14 (14)
Paris classification
   E1 Proctitis 1 (1)
   E2 Left-sided 20 (20)
   E3 Extensive 5 (5)
   E4 Pancolitis 73 (74)
Medications at time of colonoscopy
   5-aminosalicylic acid (5 ASA) 67 (68)
   Steroids 30 (30)
   Mercaptopurine/methotrexate 33 (33)
   Infliximab/adalimumab 12 (12)
   Antibiotics 10 (10)
   Five ASA Enema 5 (5)
   Hydrocortisone Enema 10 (10)
   Methotrexate 1 (1)
   Tacrolimus 3 (3)
   VSL 3 probiotic 10 (10)
Table 2  Inter-observer agreement in grading rectal disease 
severity (Mayo scores) between reviewers 
Reviewer AB Reviewer PR
0 1 2 3 Unknown Total
0 22   4   1 0   0 27
1   1 22 12 1   0 36
2   0   2   8 4   0 14
3   0   0   1 3   0   4
Unknown   0   0   0 0 18 18
Total 23 28 22 8 18 99
Table 3  Inter-observer agreement in grading sigmoid disease 
severity (Mayo score) between reviewers 
Reviewer AB Reviewer PR
0 1 2 3 Unknown Total
0 22   5   0   0 0 27
1   2 22 12   4 0 40
2   0   3   9   7 0 19
3   0   0   5   3 0   8
Unknown   0   0   0   0 5   5
Total 24 30 26 14 5 99
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the Mayo rectal endoscopic scores. This was most 
notable in the mild to moderate range of PUCAI (Figure 
2). Severe clinical disease correlated well both clinically 
and endoscopically, with no patients with PUCAIs of 
over 65 having Mayo scores of less than 2. However, 
20% of patients with rectal Mayo scores of 1 or 2 had 
PUCAIs < 10 (clinical remission), suggesting that a 
subset of patients with mild to moderate endoscopic 
disease have minimal symptoms.
While all six subcomponents of the PUCAI demon­
strated statistically significant correlation with rectal 
Mayo scores, the strongest correlations were seen with 
rectal bleeding (Pearson’s r = 0.59), stool consistency (r 
= 0.50), and number of stools (r = 0.49). The weakest 
correlation was with abdominal pain (r = 0.33). 
DISCUSSION
Our study was designed to ascertain the association 
between standardized scores of clinical and endoscopic 
disease severity in children and young adults with 
ulcerative colitis. In particular, we compared the 
Pediatric Ulcerative Colitis Activity Index (PUCAI) as 
a measure of clinical activity with the Mayo score of 
mucosal disease. We demonstrated that the degree 
of mucosal inflammation may be difficult to ascertain 
in pediatric patients with ulcerative colitis, even by 
experienced IBD endoscopists looking at the same 
endoscopic photos using a standardized guide. While 
statistically significant inter observer agreement 
existed, there was significant variability, especially with 
mild to moderate inflammation (Mayo scores of 1 and 
2). Agreement was improved in patients in endoscopic 
remission (Mayo score 0) or severe colitis (Mayo 
score 3). We also identified a statistically significant 
correlation between endoscopic and clinical severity, 
but there was also variation in clinical disease severity 
within each stratum of endoscopic severity. We also 
demonstrate that some aspects of the PUCAI score 
(e.g., rectal bleeding) correlate better with endoscopic 
severity than other more subjective components 
(abdominal pain).
Our determination of inter­rater reliability of 
endoscopic disease severity is comparable to what 
has been reported in the literature when rating adults 
with IBD. In a prospective study of endoscopic disease 
severity utilizing video endoscopy and Mayo score 
grading, the endoscopic score had the lowest inter­
Table 4  Pediatric ulcerative colitis activity index data by 
component
Characteristic mean ± SD or n  (%)
Age at time of colonoscopy (yr) 15.7 (4.1)
Days between colonoscopy and PUCAI score   14.8 (10.6)
Method of PUCAI collection
   Prospectively entered at time of clinic visit   27 (27)
   Calculated from medical record   72 (73)
Abdominal pain
   No pain   52 (53)
   Present but ignored   36 (36)
   Cannot be ignored   11 (11)
Rectal bleeding
   None   49 (49)
   Small amount, < 50%   20 (20)
   Small amount, most   27 (27)
   Large amount   3 (3)
Consistency
   Formed   57 (58)
   Partially formed   35 (35)
   Completely unformed   7 (7)
Number of stools
   0-2   61 (62)
   3-5   21 (21)
   6-8   11 (11)
   > 8   6 (6)
Nocturnal stools   18 (18)
Activity limitation   
   No limitation   62 (63)
   Occasional limitation   29 (29)
   Severe restriction   8 (8)
Overall activity
   Remission, 0-9   33 (33)
   Mild, 10-34   39 (39)
   Moderate, 35-64   23 (23)
   Severe, > 64   4 (4)
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Figure 1  Correlation between disease severity in rectum (Mayo score) 
and Pediatric ulcerative colitis activity index. PUCAI: Pediatric ulcerative 
colitis activity index.
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colitis activity index stratum. PUCAI: Pediatric ulcerative colitis activity index.
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rater reliability among four clinicians (κ = 0.38). In 
contrast, inter­rater reliability was more consistent 
in clinical aspects of the Mayo score like rectal 
bleeding[21]. Another recent paper utilizing experienced 
central readers reviewing videos demonstrated 
improved inter­rater reliability[22]. Our two clinicians 
assessing endoscopic disease severity have over 
40 years combined experience in UC colonoscopy, 
yet our agreement looking at the same photos was 
still only modest. The inter­observer variability is a 
potential pitfall of using endoscopic disease severity 
as an inclusion criterion or a primary endpoint in 
pediatric clinical trials. Whether or not central reading 
is absolutely necessary in such studies, or whether 
physicians can objectively assess disease severity by 
simply looking at photos, requires further study. 
Disease activity in ulcerative colitis has traditionally 
been assessed by clinical scoring systems, including 
the Simple clinical colitis activity index (SCCAI), Seo 
index, or clinical Mayo index[4]. For recent clinical trials 
of biologics in UC, the Mayo score (a composite index 
that includes both clinical parameters and endoscopic 
disease severity) has been the primary endpoint 
of choice. In pediatrics, the PUCAI, a well validated 
clinical scoring system has been utilized in both 
retrospective and prospective drug studies. Advantages 
of the PUCAI include its face validity, ease of use, and 
responsiveness to change. The PUCAI score after day 
5 of intravenous corticosteroid therapy can identify a 
subset of patients that will require either surgery or 
medical salvage therapy[23]. The PUCAI has also been 
utilized to demonstrate response in studies of medical 
rescue therapies (infliximab and tacrolimus)[6,24]. The 
PUCAI was also the primary endpoint in the infliximab 
trial that obtained regulatory approval. However, the 
two limitations of the PUCAI recently raised are that it 
is not a patient reported outcome, and that there is no 
mucosal healing component. 
Our current study establishes that there is a strong 
correlation between endoscopic disease severity and 
PUCAI score. Nevertheless, approximately 20% of 
patients who felt “well” in our study (i.e., had PUCAIs 
less than 10 signifying endoscopic remission), had 
mucosal inflammation. Beattie and colleagues noted a 
similar discrepancy between clinical and endoscopic 
severity in patients treated with corticosteroids[25]. 
Such patients (clinical remission but endoscopic 
inflammation) may be more likely to flare than 
those in full endoscopic remission based on adult 
data[26]. However, it is unclear whether the benefits 
of intensifying therapy (aka. “Stepping up to 
immunomodulators or biologics) outweighs the risks 
of additional immunosuppression. Another question 
is of whether adding immunosuppression in patients 
in remission but with endoscopic disease activity 
may reduce the risk of colorectal cancer, but current 
guidelines do not recommend adding thiopurines or 
biologics solely for cancer prevention[27].
Our study has several limitations due to its retro­
spective nature. Most importantly, the endoscopic 
assessment of disease severity (Mayo) and the clinical 
score (PUCAI) were not obtained at the same time. 
While we excluded patients that had major changes 
in treatment between the two assessments, we 
cannot exclude the possibility of some spontaneous 
deterioration or improvement. The endoscopic photo­
graphs were also not performed in a standardized 
manner, and in a subset of patients, photographs of the 
rectum and sigmoid were not taken. In addition, we did 
not evaluate any surrogate markers such as calprotectin 
or lactoferrin in this study which have recently been 
shown to be cost­ effective in diagnosing and monitoring 
IBD[28]. In spite of the limitations, we feel our study 
adds valuable knowledge about the association between 
clinical and endoscopic disease severity in children. We 
plan to follow up this with additional prospective studies, 
which will hopefully further address the relationship 
between endoscopic and clinical disease activity in UC. 
Endoscopic disease severity (Mayo score) assessed 
by reviewing photographs of pediatric colonoscopy has 
moderate inter­rater reliability, and agreement was less 
robust in assessing patients with mild disease activity. 
Endoscopic disease severity generally correlates 
with clinical disease severity. However, children with 
inflamed colons can have significant variation in their 
reported clinical symptoms. Thus, assessment of both 
clinical symptoms and endoscopic disease severity 
may be required in future clinical studies.
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Background
The incidence of inflammatory disease has been increasing across the world, 
particularly in children. There are no good parameters to assess the progress 
the of disease. There are also no good endpoints for drug trials in inflammatory 
bowel disease (IBD). Clinical indices like pediatric ulcerative colitis activity index 
(PUCAI) have been validated to assess disease burden. However, PUCAI 
score vary due to symptoms that may not be related to IBD. Regulatory agency 
like FDA have recommended endoscopic assessment for mucosal healing as 
end point in drug trials.
Research frontiers
Two commonly utilized indices to assess ulcerative colitis are the pediatric 
ulcerative colitis activity index (PUCAI, a clinical score) and the Mayo 
endoscopic score (endoscopic disease activity). Little data exists on inter-
rater reliability of the Mayo score for assessing pediatric disease, or on the 
correlation between the PUCAI and Mayo score.
Innovations and breakthroughs
The authors demonstrated significant variability in degree of mucosal 
inflammation by endoscopy in patients with mild to moderate inflammation. 
There is a strong correlation between endoscopic disease severity and PUCAI 
score. However, approximately 20% of patients with remission as per PUCAI 
score had mucosal inflammation.
Applications
Clinical indices like PUCAI are not good end points for assessing disease 
activity or out comes in drug trial of ulcerative colitis. Mayo endoscopic score 
are associated intra observer variance especially in intermediate disease. A 
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score that is combination of clinical indices and endoscopic assessment may 
be good to determine the outcomes. Endoscopic disease activity score may be 
better end points than clinical indices for drug trials in IBD.
Peer-review
The manuscript is well written and interesting. 
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